Avai Bio FY26 net loss widens 53% to USD 1.75 million
AVAI•FY26 results and cash position
- Avai Bio posted a net loss of USD 1.75 million, widening 53% from fiscal 2025.
- Operating expenses slipped 3% to USD 1.48 million; revenue was no revenue.
- Other income fell to USD 0 from USD 450,000, while other expenses more than quadrupled to USD 269,318 on higher convertible notes.
- Cash declined to USD 23,145, while the working capital deficit widened to USD 3.3 million.
- Net cash used in operating activities narrowed 13% to USD 1.01 million; financing cash inflows fell 23% to USD 951,936.
